SAS Output

21-JUL-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

55% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1558 808 52% 1460 -98 1292 -266
ERLYTX 76 163 214% 294 218 220 144
GI 476 106 22% 191 -284 193 -283
GU 450 275 61% 496 46 595 145
GYN 57 0 0% 0 -57 0 -57
LEUK 150 47 31% 84 -65 79 -71
LUNG 524 199 38% 359 -164 347 -177
LYMPH 172 3 2% 5 -166 12 -160
MELAN 55 648 1178% 1170 1115 1056 1001
MMYEL 147 43 29% 77 -69 81 -66
OTHER 0 19   34 34 32 32
Total 3665 2311   4170 510 3907 242

21-JUL-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

55% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 2   3 3 2 2
BREAST 37 4 11% 7 -29 9 -28
Breast 0 7   12 12 7 7
CCD 0 868   1568 1568 1567 1567
GU 0 0   0 0 0 0
LEUK 69 3 4% 5 -63 4 -65
LUNG 43 324 753% 585 542 616 573
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 10   18 18 11 11
PREV 0 43   77 77 67 67
SURV 0 40   72 72 60 60
SXQOL 878 10 1% 18 -859 45 -833
Total 1172 1311   2365 1196 2388 1216

21-JUL-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

55% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 2   3 3 2 2
BREAST 1595 812 51% 1467 -127 1301 -294
Breast 0 7   12 12 7 7
CCD 0 868   1568 1568 1567 1567
ERLYTX 76 163 214% 294 218 220 144
GI 476 106 22% 191 -284 193 -283
GU 450 275 61% 496 46 595 145
GYN 57 0 0% 0 -57 0 -57
LEUK 219 50 23% 90 -128 83 -136
LUNG 567 523 92% 945 378 963 396
LYMPH 225 3 1% 5 -219 12 -213
MELAN 55 648 1178% 1170 1115 1056 1001
MMYEL 239 43 18% 77 -161 81 -158
OTHER 0 29   52 52 43 43
PREV 0 43   77 77 67 67
SURV 0 40   72 72 60 60
SXQOL 878 10 1% 18 -859 45 -833
Total 4837 3622   6537 1706 6295 1458

21-JUL-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

55% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1012 339 33% 612 -399 491 -521
ERLYTX 76 112 147% 202 126 169 93
GI 418 84 20% 151 -266 156 -262
GU 375 195 52% 352 -22 405 30
GYN 57 0 0% 0 -57 0 -57
LEUK 122 36 30% 65 -56 65 -57
LUNG 441 137 31% 247 -193 226 -215
LYMPH 129 3 2% 5 -123 12 -117
MELAN 55 360 655% 650 595 575 520
MMYEL 85 43 51% 77 -7 81 -4
OTHER 0 19   34 34 32 32
Total 2770 1328   2395 -368 2212 -558

21-JUL-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

55% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 2   3 3 2 2
BREAST 10 4 40% 7 -2 9 -1
Breast 0 7   12 12 7 7
CCD 0 809   1461 1461 1508 1508
GU 0 0   0 0 0 0
LEUK 69 3 4% 5 -63 4 -65
LUNG 30 227 757% 410 380 379 349
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 10   18 18 11 11
PREV 0 33   59 59 48 48
SURV 0 30   54 54 42 42
SXQOL 740 10 1% 18 -721 45 -695
Total 994 1135   2047 1056 2055 1061

21-JUL-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

55% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 2   3 3 2 2
BREAST 1022 343 34% 619 -402 500 -522
Breast 0 7   12 12 7 7
CCD 0 809   1461 1461 1508 1508
ERLYTX 76 112 147% 202 126 169 93
GI 418 84 20% 151 -266 156 -262
GU 375 195 52% 352 -22 405 30
GYN 57 0 0% 0 -57 0 -57
LEUK 191 39 20% 70 -120 69 -122
LUNG 471 364 77% 657 186 605 134
LYMPH 182 3 2% 5 -176 12 -170
MELAN 55 360 655% 650 595 575 520
MMYEL 177 43 24% 77 -99 81 -96
OTHER 0 29   52 52 43 43
PREV 0 33   59 59 48 48
SURV 0 30   54 54 42 42
SXQOL 740 10 1% 18 -721 45 -695
Total 3764 2463   4442 685 4267 503

21-JUL-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

55% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 65 672 1034% 1214 1149 1124 1059
Breast 0 7   12 12 7 7
CCD 0 868   1568 1568 1567 1567
GI 81 16 20% 28 -52 34 -47
GU 215 30 14% 54 -160 50 -165
LEUK 0 3   5 5 4 4
LUNG 53 59 111% 106 53 140 87
LYMPH 7 1 14% 1 -5 7 0
MELAN 0 589   1064 1064 966 966
MMYEL 0 43   77 77 81 81
OTHER 0 17   30 30 28 28
PREV 0 43   77 77 67 67
SURV 0 40   72 72 60 60
SXQOL 878 10 1% 18 -859 45 -833
Total 1299 2398   4326 3031 4180 2881

21-JUL-2017 18:11

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

The REPORT Procedure

Detailed and/or summarized report

Table 1

Comm. Phase Study Stat
Center
Open
Date
Months
Open
Total
Regs
Accrual
Goal
Monthly
Accrual
Rate
Date of
Expected Closure or
Temporary Closure
    A221405 ALLIANCE     2      
BREAST II A011203 Breast, Adv, Tam vs Endoxifen ALLIANCE 27JAN2015:00:00:00   7   0.2  
    S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 SWOG 07JUL2016:00:00:00 12 112 333 14.8 Sep-2018
  III A011106 Breast, Neoadj, ALTERNATE study ALLIANCE 15FEB2014:00:00:00   41   1.8  
    A011202 Breast, Nodal XRT +/- ALND ALLIANCE     51      
    A011401 Breast, adj, Stage II/III HER2-, weight loss ALLIANCE 29AUG2016:00:00:00   57   7.7  
    B51 Breast, Regional Nodal XRT NRG     15      
    B55 Brst, Adj Olaparib for BRCA,TNBC NRG 03JUL2014:00:00:00   18   1.2  
    E2112 Brst,Adv,Exemestane+/-Entinostat ECOG-ACR 02JAN2014:00:00:00   35   1.5  
    NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG 22JAN2015:00:00:00   38   2.0  
    S1007 Breast,Adj,N1,Endocrine+/-Chemo SWOG 15JAN2011:00:00:00 78 4976 4000 47.2 Nov-2015
    S1207 Brst,Adj,Endocrine+/-Everolimus SWOG 03SEP2013:00:00:00 46 1288 1900 37.5 Nov-2018
    S1222 Brst,Fulv. +/- Ever. +/- Anastr. SWOG 09MAY2014:00:00:00   37 840   Feb-2015 Temp Close
    S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) SWOG 15NOV2016:00:00:00 8 41 1000 6.8 Mar-2029
  OTHER E1Z11 Brst,Genetic Predictors of AIMSS ECOG-ACRIN 10MAY2013:00:00:00   142   0.7  
Breast III A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo ALLIANCE 08DEC2016:00:00:00   7   1.2  
CCD III A011104 Preoperative Breast MRI ALLIANCE 21FEB2014:00:00:00   9   0.7  
    S1415CD TrACER CSF Standing Order Intervention for FN SWOG 01SEP2016:00:00:00 10 639 3960 90.5 Jul-2020
  OTHER S1417CD Colorectal, Cost Cohort Study SWOG 13MAY2016:00:00:00 14 75 374 9.5 Feb-2020
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 06AUG2015:00:00:00   5   0.2  
    S1609 Rare Tumor, Comb Nivo/Ipi SWOG 13JAN2017:00:00:00 6 111 334 18.5 Jul-2018
  II-III A071102 GBM, adj TMZ +/- Veliparib ALLIANCE 19SEP2014:00:00:00   37   0.0  
    ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) COG 16MAY2014:00:00:00   4   0.3  
  OTHER EAY131 MATCH ECOG-ACR 12AUG2015:00:00:00   95   7.3  
GI II A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT ALLIANCE 01DEC2016:00:00:00   2   0.3  
    E7208 CRC,Adv, Irino/Cet+/-Ramucirumab ECOG-ACRIN 20FEB2014:00:00:00   23   0.8  
    EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo ECOG-ACRIN 29JAN2016:00:00:00   1   0.2  
    EA2142 GI NEC, Adv G3, EP vs TMZ + CAP ECOG-ACRIN 06NOV2015:00:00:00   2   0.2  
    NRGGI002 Rectal, Ph II, Sensitization using TNT NRG 12OCT2016:00:00:00   2   0.3  
    S1505 Panc,Resect, Perioperative Chemo SWOG 12OCT2015:00:00:00 21 80 112 0.2 > 15 Yrs
    S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 SWOG 01SEP2016:00:00:00 10 63 143 9.3 Mar-2018
  II-III N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX ALLIANCE 13JAN2012:00:00:00   121   2.3  
  III R0848 Panc, Adj, Erlotinib v ChemoRT NRG 01MAR2014:00:00:00   20   0.0  
GU II EA8141 UTUC, HG, Chemo then Surg ECOG-ACR 27JAN2015:00:00:00   8   0.3  
    S1314 Blad, COXEN Neoadj. Chemo + Cyst SWOG 11JUL2014:00:00:00 36 208 230 8.7 Sep-2017
    S1500 pRCC,Adv, Sunitinib vs MET inhib SWOG 05APR2016:00:00:00 15 43 180 3.2 Feb-2021
    S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab SWOG 07FEB2017:00:00:00 5 6 148 1.1 Apr-2028
  III A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) ALLIANCE 01JUL2015:00:00:00   2   0.2  
    E2810 Renal, Pazopanib vs Placebo ECOG-ACRIN 17APR2012:00:00:00   48   0.5  
    R0924 Pros, NADT+WPRT vs. NADT+P&SV RT NRG 07JUL2011:00:00:00   47   1.8  
    S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG SWOG 07FEB2017:00:00:00 5 13 969 2.4 > 15 Yrs
LEUK I S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP SWOG 01APR2014:00:00:00 39 36 38 0.8 Sep-2017
  I-II S1318 ALL, Age 65+, Ph±, Blinatumomab SWOG 12JAN2015:00:00:00 30 44 44 3.8 Jul-2017
  II S0919 Rel AML: Pravastatin+Ida+Ara-C SWOG 15AUG2009:00:00:00 95 115 110 0.2 Feb-2015
  III E1910 BCR-ABL-neg, B ALL, Blinatumomab ECOG-ACRIN 23DEC2013:00:00:00   62   2.7  
    E2906 AML, Age 60+, Clo vs Dauno+Cy ECOG-ACRIN 24FEB2011:00:00:00   75   0.0  
  OTHER NHLBIMDS LEUK, National MDS Study ECOG-ACRIN 05APR2016:00:00:00   4   0.5  
LUNG I-II 8811 NSCLC, Stage III,ChemoRT+ABT-888 SWOG 02JAN2013:00:00:00 54 46 162 3.2 Jul-2020
  II R1306 NSCLC,Adv,ALK/EGFR,TargetAgents NRG 04NOV2013:00:00:00   8   0.0  
    S1400G HRRD: Talazoparib (BMN 673) SWOG 07FEB2017:00:00:00 5 23 60 4.2 Mar-2018
    S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel SWOG 18JUL2016:00:00:00   37 53   Jun-2017 Temp Close
  II-III NRGCC003 SCLC, PCI or HA-PCI NRG 07DEC2015:00:00:00   3   0.3  
    S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab SWOG 25MAR2015:00:00:00 27 129 605 8.0 Jun-2022
  III A081105 ALCHEMIST1, EGFR mut, Erlotinib ALLIANCE 02JAN2014:00:00:00   24   1.7  
    C140503 NSCL, Lobect v Sublobar resect ALLIANCE 09JUL2007:00:00:00   27   0.0  
    C30607 NSCL,Adv Main Sunitinib v Placbo ALLIANCE     2      
    C30610 SCLC, Thoracic RT ALLIANCE 21MAR2008:00:00:00   51   0.2  
    E4512 ALCHEMIST2, ALK mut, Crizotinib ECOG-ACR 18AUG2014:00:00:00   4   0.2  
    EA5142 ALCHEMIST3, Non-match, Nivolumab ECOG-ACRIN 16MAY2016:00:00:00   14   1.3  
    S1400I Non-Match: Nivo + Ipi vs Nivo SWOG 18DEC2015:00:00:00 19 211 350 8.5 Nov-2018
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 06FEB2014:00:00:00   330   17.5  
    S1400 SCCA,Adv, Biomarker Master SWOG 15JUN2014:00:00:00 37 1330   31.2  
LYMPH III A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo ALLIANCE 15JUL2016:00:00:00   1   0.2  
MELAN II E3612 MELAN,Adv Ipilimumab±Bevacizumab ECOG-ACR     5      
    S1320 Adv, BRAF mut, Inter v Contin SWOG 22JUL2014:00:00:00 35 162 280 5.5 Apr-2019
    S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) SWOG 20OCT2016:00:00:00 9 1 77 0.2 > 15 Yrs
    S1616 MELAN,, Adv, Ipilimumab ± Nivolumab SWOG 17JUL2017:00:00:00 0 0 94    
  II-III EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 01MAR2016:00:00:00   36   3.5  
  III EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T ECOG-ACR 15DEC2015:00:00:00   16   0.5  
    S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 SWOG 15OCT2015:00:00:00 21 1194 1378 85.5 Sep-2017
MMYEL I-II S1211 MM,High Risk, RVD+/-ELO SWOG 27OCT2012:00:00:00   142 110   Jun-2016 Temp Close
  III E1A11 MM, frontline, BLD vs CLD ECOG-ACRIN 22NOV2013:00:00:00   128   6.3  
    E3A06 AMM, Lenalidomide vs Observation ECOG-ACRIN 08NOV2010:00:00:00   35   0.3  
OTHER I-II A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II ALLIANCE 26JAN2015:00:00:00   6   0.7  
  II A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo ALLIANCE 02SEP2014:00:00:00   1   0.0  
    A091305 HN, Adv, Thyroid PPAR agonist + Chemo ALLIANCE 01SEP2014:00:00:00   2   0.2  
    A091401 Sarc, ALLIANCE 18JUN2015:00:00:00   5   0.0  
    A091404 HN, AR+, Enzalutamide ALLIANCE 25SEP2015:00:00:00   3   0.5  
    AOST1521 Osteo CDX-011 in Rec/Ref Dz,Ph 2 COG 02JUL2015:00:00:00   3   0.0  
    E3311 Oroph,Srg + Low or Std IMRT ECOG-ACRIN 01MAR2014:00:00:00   38   0.3  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   1   0.2  
    NRGBN001 HN, novel vs. std chemoradiation + chemo NRG 28AUG2015:00:00:00   1   0.0  
    NRGHN002 HN, Adv, Orophyx RT vs RT+ Chemo NRG 27OCT2014:00:00:00   1   0.0  
  II-III G0281 Ovar, Recur/prog LG, IC chemo vs trametinib NRG 27FEB2014:00:00:00   1   0.2  
    G0286B Adv Endometrial,Metformin/Chemo NRG     1      
    NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG 06FEB2016:00:00:00   3   0.2  
    NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG 21APR2014:00:00:00   3   0.2  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   3   0.0  
  III N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC ALLIANCE     4      
    NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo NRG 04FEB2016:00:00:00   4   0.2  
    R0724 Cervical, Chem+RT +/- Adj. Chemo NRG 15JAN2014:00:00:00   1   0.0  
    R0920 HN, Adv, Postop IMRT ± Cetuximab NRG 24DEC2013:00:00:00   10   0.2  
  OTHER EAQ152 Communication & education in tumor profiling ECOG-ACR 26SEP2016:00:00:00   11   1.7  
PREV II EA1141 Breast, Abbrev. MRI vs Digital Tomosynthesis ECOG-ACR 02SEP2016:00:00:00   7   1.2  
  III A211102 Breast, Atypia via RPFNA, Metformin v Placebo ALLIANCE 01FEB2015:00:00:00   3   0.2  
    S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac SWOG 01MAR2013:00:00:00 52 154 480 5.3 Aug-2022
  OTHER A211201 Breast Density, MA.32 companion ALLIANCE 22AUG2012:00:00:00   14   0.0  
SURV III E1Q11 EROS: Reproductive Health in Cancer Survivors ECOG-ACR 30SEP2015:00:00:00   4   0.7  
  OTHER S1316 Compar. Effectiv. Trial for MBO SWOG 09MAR2015:00:00:00 28 92 200 5.7 Feb-2019
SXQOL III A221101 Glioma, Nuvigil/Placebo Fatigue ALLIANCE 03JUN2013:00:00:00   15   0.2  
    A221102 Brst,AI Arthralgia,Testosterone ALLIANCE 07SEP2012:00:00:00   10   0.2  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

21-JUL-2017 18:11

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

The REPORT Procedure

Detailed and/or summarized report

Table 1

Phase Comm. Int
grp
Stat
Center
Study NCIPROTO CA
Cntrl
Study
Temp
Close
OTHER BREAST Y ECOG-ACRIN E1Z11 Brst,Genetic Predictors of AIMSS E1Z11 Y  
  CCD N   S1417CD Colorectal, Cost Cohort Study   Y  
  ERLYTX Y ECOG-ACR EAY131 MATCH EAY131 N  
  LEUK Y ECOG-ACRIN NHLBIMDS LEUK, National MDS Study NHLBI-MDS Y  
  LUNG Y SWOG S1400 SCCA,Adv, Biomarker Master S1400 N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  OTHER Y ECOG-ACR EAQ152 Communication & education in tumor profiling EAQ152 Y  
  PREV Y ALLIANCE A211201 Breast Density, MA.32 companion A211201 Y  
  SURV Y SWOG S1316 Compar. Effectiv. Trial for MBO S1316 Y  
I LEUK N   S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP   N  
I-II LEUK Y SWOG S1318 ALL, Age 65+, Ph±, Blinatumomab S1318 N  
  LUNG N   8811 NSCLC, Stage III,ChemoRT+ABT-888   N  
  MMYEL Y SWOG S1211 MM,High Risk, RVD+/-ELO S1211 N Y
  OTHER Y ALLIANCE A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II A091304 N  
II BREAST Y SWOG S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 S1416 N  
    Y ALLIANCE A011203 Breast, Adv, Tam vs Endoxifen A011203 N  
  ERLYTX Y SWOG S1609 Rare Tumor, Comb Nivo/Ipi S1609 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
  GI Y SWOG S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 S1513 N  
    Y SWOG S1505 Panc,Resect, Perioperative Chemo S1505 N  
    Y ECOG-ACRIN E7208 CRC,Adv, Irino/Cet+/-Ramucirumab E7208 N  
    Y ECOG-ACRIN EA2142 GI NEC, Adv G3, EP vs TMZ + CAP EA2142 N  
    Y NRG NRGGI002 Rectal, Ph II, Sensitization using TNT NRG-GI002 N  
    Y ALLIANCE A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT A021501 N  
    Y ECOG-ACRIN EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo EA2133 Y  
  GU Y SWOG S1314 Blad, COXEN Neoadj. Chemo + Cyst S1314 N  
    Y SWOG S1500 pRCC,Adv, Sunitinib vs MET inhib S1500 N  
    Y SWOG S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab S1605 N  
    Y ECOG-ACR EA8141 UTUC, HG, Chemo then Surg EA8141 N  
  LEUK N   S0919 Rel AML: Pravastatin+Ida+Ara-C   N  
  LUNG Y SWOG S1400G HRRD: Talazoparib (BMN 673) S1400G N  
    Y SWOG S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel S1507 N Y
    Y NRG R1306 NSCLC,Adv,ALK/EGFR,TargetAgents RTOG-1306 N  
  MELAN Y SWOG S1320 Adv, BRAF mut, Inter v Contin S1320 N  
    Y SWOG S1616 MELAN,, Adv, Ipilimumab ± Nivolumab S1616 N  
    Y SWOG S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) S1512 N  
    Y ECOG-ACR E3612 MELAN,Adv Ipilimumab±Bevacizumab E3612 N  
  OTHER Y ECOG-ACRIN E3311 Oroph,Srg + Low or Std IMRT E3311 Y  
    Y NRG NRGBN001 HN, novel vs. std chemoradiation + chemo NRG-BN001 N  
    Y COG AOST1521 Osteo CDX-011 in Rec/Ref Dz,Ph 2 AOST1521 N  
    Y ALLIANCE A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo A091202 N  
    Y ALLIANCE A091401 Sarc, A091401 N  
    Y ALLIANCE A091305 HN, Adv, Thyroid PPAR agonist + Chemo A091305 N  
    Y ALLIANCE A091404 HN, AR+, Enzalutamide A091404 N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
    Y NRG NRGHN002 HN, Adv, Orophyx RT vs RT+ Chemo NRG-HN002 Y  
  PREV Y ECOG-ACR EA1141 Breast, Abbrev. MRI vs Digital Tomosynthesis EA1141 Y  
II-III ERLYTX Y ALLIANCE A071102 GBM, adj TMZ +/- Veliparib A071102 N  
    Y COG ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) ARST1321 N  
  GI Y ALLIANCE N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX N1048 Y  
  LUNG Y SWOG S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab S1403 N  
    Y NRG NRGCC003 SCLC, PCI or HA-PCI NRG-CC003 Y  
  MELAN Y ECOG-ACRIN EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG-GY005 Y  
    Y NRG G0286B Adv Endometrial,Metformin/Chemo GOG-0286B Y  
    Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG-HN001 Y  
    Y NRG G0281 Ovar, Recur/prog LG, IC chemo vs trametinib GOG-0281 Y  
III BREAST N   S1222 Brst,Fulv. +/- Ever. +/- Anastr.   N Y
    Y SWOG S1207 Brst,Adj,Endocrine+/-Everolimus S1207 Y  
    Y SWOG S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) S1418 Y  
    Y SWOG S1007 Breast,Adj,N1,Endocrine+/-Chemo S1007 Y  
    Y ALLIANCE A011202 Breast, Nodal XRT +/- ALND A011202    
    Y ALLIANCE A011106 Breast, Neoadj, ALTERNATE study A011106 N  
    Y NRG B51 Breast, Regional Nodal XRT NSABP-B-51 Y  
    Y ALLIANCE A011401 Breast, adj, Stage II/III HER2-, weight loss A011401 Y  
    Y NRG NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG-BR003 N  
    Y ECOG-ACR E2112 Brst,Adv,Exemestane+/-Entinostat E2112 Y  
    Y NRG B55 Brst, Adj Olaparib for BRCA,TNBC NSABP-B-55 Y  
  Breast Y ALLIANCE A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo A011502 Y  
  CCD Y SWOG S1415CD TrACER CSF Standing Order Intervention for FN S1415CD Y  
    Y ALLIANCE A011104 Preoperative Breast MRI A011104 Y  
  GI Y NRG R0848 Panc, Adj, Erlotinib v ChemoRT RTOG-0848 Y  
  GU Y SWOG S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG S1602 Y  
    Y ECOG-ACRIN E2810 Renal, Pazopanib vs Placebo E2810 Y  
    Y NRG R0924 Pros, NADT+WPRT vs. NADT+P&SV RT RTOG-0924 Y  
    Y ALLIANCE A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) A031102 Y  
  LEUK Y ECOG-ACRIN E2906 AML, Age 60+, Clo vs Dauno+Cy E2906 Y  
    Y ECOG-ACRIN E1910 BCR-ABL-neg, B ALL, Blinatumomab E1910 N  
  LUNG Y SWOG S1400I Non-Match: Nivo + Ipi vs Nivo S1400I Y  
    Y ALLIANCE C30610 SCLC, Thoracic RT CALGB-30610 Y  
    Y ALLIANCE C30607 NSCL,Adv Main Sunitinib v Placbo CALGB-30607 Y  
    Y ALLIANCE C140503 NSCL, Lobect v Sublobar resect CALGB-140503    
    Y ALLIANCE A081105 ALCHEMIST1, EGFR mut, Erlotinib A081105 N  
    Y ECOG-ACRIN EA5142 ALCHEMIST3, Non-match, Nivolumab EA5142 N  
    Y ECOG-ACR E4512 ALCHEMIST2, ALK mut, Crizotinib E4512 N  
  LYMPH Y ALLIANCE A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo A051301 N  
  MELAN Y SWOG S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 S1404 Y  
    Y ECOG-ACR EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T EA6134 Y  
  MMYEL Y ECOG-ACRIN E3A06 AMM, Lenalidomide vs Observation E3A06 Y  
    Y ECOG-ACRIN E1A11 MM, frontline, BLD vs CLD E1A11 Y  
  OTHER Y NRG R0920 HN, Adv, Postop IMRT ± Cetuximab RTOG-0920 Y  
    Y ALLIANCE N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC N0577 N  
    Y NRG R0724 Cervical, Chem+RT +/- Adj. Chemo RTOG-0724 Y  
    Y NRG NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo NRG-GY004 Y  
  PREV Y SWOG S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac S0820 Y  
    Y ALLIANCE A211102 Breast, Atypia via RPFNA, Metformin v Placebo A211102 Y  
  SURV Y ECOG-ACR E1Q11 EROS: Reproductive Health in Cancer Survivors E1Q11 Y  
  SXQOL Y ALLIANCE A221101 Glioma, Nuvigil/Placebo Fatigue A221101 Y  
    Y ALLIANCE A221102 Brst,AI Arthralgia,Testosterone A221102 Y  
    Y ALLIANCE A221405 A221405    

21-JUL-2017 18:11

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

The REPORT Procedure

Detailed and/or summarized report

Table 1

Protocol
Number
Study Accrual
Goal
Open
Stat/Date
Months
Open
Accrual
as of
01Jan02
Current Accrual Proj.
Annual
Accr.
Rate
EXPCLOSE Proj.
Study
Duration
(Years)
S0820 S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac (PREV) 480 Y-03/01/13 52 154 154 64 Aug-2022 9.5
S1007 S1007 Breast,Adj,N1,Endocrine+/-Chemo (BREAST) 4000 Y-01/15/11 78 4976 4976 566 Nov-2015 4.9
S1207 S1207 Brst,Adj,Endocrine+/-Everolimus (BREAST) 1900 Y-09/03/13 46 1288 1288 450 Nov-2018 5.2
S1222 Brst,Fulv. +/- Ever. +/- Anastr. (BREAST) 840 T-05/09/14 38 37 37 0 > 15 Yrs > 15 Yrs
S1400I S1400I Non-Match: Nivo + Ipi vs Nivo (LUNG) 350 Y-12/18/15 19 211 211 102 Nov-2018 2.9
S1403 S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab (LUNG) 605 Y-03/25/15 27 129 129 96 Jun-2022 7.2
S1404 S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 (MELAN) 1378 Y-10/15/15 21 1194 1194 1026 Sep-2017 1.9
S1415CD S1415CD TrACER CSF Standing Order Intervention for FN (CCD) 3960 Y-09/01/16 10 639 639 1086 Jul-2020 3.9
S1418 S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) (BREAST) 1000 Y-11/15/16 8 41 41 82 Mar-2029 12.4
S1602 S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG (GU) 969 Y-02/07/17 5 13 13 28.487713 > 15 Yrs > 15 Yrs
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.